Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. (Q53633828)

16 May 2018

title

Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. (English)

1 reference

16 May 2018

author name string

Avihingsanon Y

1

1 reference

16 May 2018

Phumesin P

2

1 reference

16 May 2018

Benjachat T

3

1 reference

16 May 2018

Akkasilpa S

4

1 reference

16 May 2018

Kittikowit V

5

1 reference

16 May 2018

Praditpornsilpa K

6

1 reference

16 May 2018

Wongpiyabavorn J

7

1 reference

16 May 2018

Eiam-Ong S

8

1 reference

16 May 2018

Hemachudha T

9

1 reference

16 May 2018

Tungsanga K

10

1 reference

16 May 2018

Hirankarn N

11

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 February 2006

1 reference

16 May 2018

published in

Kidney International

1 reference

16 May 2018

volume

69

1 reference

16 May 2018

issue

4

1 reference

16 May 2018

page(s)

747-753

1 reference

16 May 2018

Treatment of lupus nephritis-the advantages of a flexible approach

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Management of lupus nephritis: an update

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Flares in lupus nephritis: Incidence, impact on renal survival and management

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Clinical and prognostic value of serial renal biopsies in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lpr mice

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Requirement of the chemokine receptor CXCR3 for acute allograft rejection

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Chemokine blockade as a therapy for renal disease

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

SERUM LEVELS OF IFN-INDUCIBLE PROTEIN-10 RELATING TO THE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells.

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

TGF-beta and the endothelium during immune injury

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Renal mRNA levels as prognostic tools in kidney diseases.

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Urine chemokines as biomarkers of human systemic lupus erythematosus activity

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Outcome criteria for lupus nephritis trials: a critical overview

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Renal biopsy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038/SJ.KI.5000132

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000132

1 reference

16 May 2018

1 reference

16 May 2018